AIM ImmunoTech Company Description
AIM ImmunoTech Inc., an immuno-pharma company, focuses on the research and development of therapeutics to treat multiple types of cancers, viral diseases, and immune-deficiency disorders in the United States.
Its flagship products are Ampligen (rintatolimod), a drug of large macromolecular double-stranded ribonucleic acid molecules to treat chronic fatigue syndrome; and Alferon N Injection (Interferon alfa), a purified, natural-source, glycosylated, multi-species alpha interferon product for the treatment of genital warts.
The company is also developing Ampligen for potential treatment of pancreatic, renal cell carcinoma, malignant melanoma, non-small cell lung, ovarian, breast, colorectal, and prostate cancers, as well as for myalgic encephalomyelitis, Hepatitis B, HIV, COVID-19, and post-COVID conditions.
The company was formerly known as Hemispherx Biopharma, Inc. and changed its name to AIM ImmunoTech Inc. in August 2019.
AIM ImmunoTech Inc. was incorporated in 1966 and is headquartered in Ocala, Florida.
Country | United States |
Founded | 1966 |
Industry | Biological Products, Except Diagnostic Substances |
Employees | 23 |
CEO | Thomas Equels |
Contact Details
Address: 2117 SW Highway 484 Ocala, Delaware 34473 United States | |
Phone | 352 448 7797 |
Website | aimimmuno.com |
Stock Details
Ticker Symbol | AIMID |
Exchange | OTCMKTS |
Fiscal Year | January - December |
Reporting Currency | USD |
SIC Code | 2836 |
Key Executives
Name | Position |
---|---|
Thomas Equels | Chief Executive Officer |
Robert Dickey | Chief Financial Officer |
Peter Rodino | Chief Operating Officer |
Ann Marie Coverly | Head of Investor Relations |